Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence

References

• Mallinckrodt ARD LLC. Acthar^® Gel (RCI) [Prescribing Information]. Bedminster, NJ: Mallinckrodt ARD LLC; 2021.
   Google Scholar
• Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol Ther. 2020;7(2):327–344. doi:10.1007/s40744-020-00199-3
   PubMed Web of Science ®Google Scholar
• Fiechtner JM, Montroy T. Six months’ treatment of moderately to severely active systemic lupus erythematosus with repository corticotropin injection: an extension of a single-site, open-label trial. J Immunol Clin Res. 2016;3(1):1025–1030.
   Google Scholar
• Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–1980.
   PubMed Web of Science ®Google Scholar
• Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S consensus report. Epilepsia. 2010;51(10):2175–2189.
   PubMed Web of Science ®Google Scholar
• Shields WD. Infantile spasms: little seizures, big consequences. Epilepsy Curr. 2006;6(3):63–69.
   PubMedGoogle Scholar
• Patel AD, Berg AT, Billinghurst L, et al. Quality improvement in neurology: child neurology quality measure set: executive summary. Neurology. 2018;90(2):67–73.
   PubMed Web of Science ®Google Scholar
• Hodgeman RM, Kapur K, Paris A, et al. Effectiveness of once-daily high-dose ACTH for infantile spasms. Epilepsy Behav. 2016;59:4–8.
   PubMed Web of Science ®Google Scholar
• Knupp KG, Leister E, Coryell J, et al. Pediatric Epilepsy Research Consortium. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia. 2016;57(11):1834–1842. doi:10.1111/epi.13557
   PubMed Web of Science ®Google Scholar
• Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment of infantile spasms. Epileptic Disord. 2015;17(1):52–57. doi:10.1684/epd.2014.0723
   PubMed Web of Science ®Google Scholar
• Snead OC, Benton JW, Hosey LC, et al. Treatment of infantile spasms with high-dose ACTH: efficacy and plasma levels of ACTH and cortisol. Neurology. 1989;39(8):1027–1031. doi:10.1212/WNL.39.8.1027
   PubMed Web of Science ®Google Scholar
• Hrachovy RA, Frost JD, Kellaway P, Zion T. A controlled study of ACTH therapy in infantile spasms. Epilepsia. 1980;21(6):631–636. doi:10.1111/j.1528-1157.1980.tb04316.x
   PubMed Web of Science ®Google Scholar
• Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016;79(3):475–484. doi:10.1002/ana.24594
   PubMed Web of Science ®Google Scholar
• Ryan N, Coryell J, Mytinger J, Nickels K, Knupp K The National Infantile Spasms Consortium (NISC): moving towards standardization of care and improved treatment and outcomes in infantile spasms [abstract 3.223]. Abstract presented at: 68th Annual Meeting of the American Epilepsy Society; December 5-9, 2014; Seattle, WA.
   Google Scholar
• Baram TZ, Mitchell WC, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996;97(3):375–379. doi:10.1542/peds.97.3.375
   PubMed Web of Science ®Google Scholar
• Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr. 1983;103(4):641–655. doi:10.1016/S0022-3476(83)80606-4
   PubMed Web of Science ®Google Scholar
• Nazareth T, Philbin M, Gallagher J, Heap K, Carroll S, Boing E Medical resource utilization in patients with infantile spasms after receipt of repository corticotropin injection (Acthar Gel): results of a physician survey. Poster presented at: Annual AAN meeting; April 22-28, 2017a; Boston, MA.
   Google Scholar
• Gold LS, Schepman PB, Wang W-J, et al. Healthcare costs and resource utilization in patients with infantile spasms treated with H.P. Acthar Gel®. Adv Ther. 2016;33(8):1293–1304. doi:10.1007/s12325-016-0361-2
   PubMed Web of Science ®Google Scholar
• Damal K, Stoker E, Foley J. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics: Targets Therapy. 2013;7:247–258.
   PubMedGoogle Scholar
• Berkovich RR. Acute multiple sclerosis relapse.Continuum. 2016;22(3):799–814.
   PubMedGoogle Scholar
• Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics. 2013;10(1):97–105.
   PubMed Web of Science ®Google Scholar
• Kaplan J, Miller T, Baker M, Due B, Zhao E. A prospective observational registry of repository corticotropin injection (Acthar® Gel) for the treatment of multiple sclerosis relapse. Front Neurol. 2020;11:598496.
   PubMed Web of Science ®Google Scholar
• Nazareth T, Datar M, Yu T-C. Treatment effectiveness for resolution of multiple sclerosis relapse in a US health plan population. Neurol Ther. 2019;8(2):383–395.
   PubMed Web of Science ®Google Scholar
• Kutz C. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Ther Adv Chronic Dis. 2016;7(4):190–197.
   PubMed Web of Science ®Google Scholar
• Wynn D, Goldstick L, Bauer W, et al. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. CNS Neurosci Ther. 2022;28(3):364–371.
   PubMed Web of Science ®Google Scholar
• Gold LS, Suh K, Schepman PB, Damal K, Hansen RN. Healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with Acthar Gel®. Adv Ther. 2016b;33(8):1279–1292.
   PubMed Web of Science ®Google Scholar
• Wan GJ, Chopra I, Niewoehner J, Hunter SF. Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis. Drugs Context. 2020;9:2020-9–4.
   Google Scholar
• Hunter SF, Bindra J, Chopra I, Niewoehner J, Panaccio MP, Wan GJ. Cost-effectiveness of repository corticotropin injection for the treatment of acute exacerbations in multiple sclerosis. Clinicoecon Outcomes Res. 2021;13:883–892.
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Association of America. Treating multiple sclerosis relapses. Available from: https://mymsaa.org/ms-information/treatments/relapses/. Accessed January 13, 2023.
   Google Scholar
• National Multiple Sclerosis Society. Managing relapses. Available from: https://www.nationalmssociety.org/Treating-MS/Managing-Relapses#section-2. Accessed January 13, 2023.
   Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence, National Collaborating Centre for Chronic Conditions. Rheumatoid Arthritis: national Clinical Guideline for Management and Treatment in Adults. London: Royal College of Physicians; 2009. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0009576/pdf/PubMedHealth_PMH0009576.pdf. Accessed October 2, 2015.
   Google Scholar
• Gillis T, Crane M, Hinkle C, Wei N. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action. Open Access Rheumatol. 2017;9:131–138.
   PubMed Web of Science ®Google Scholar
• Furst DE, Wan GJ, Panaccio MP, et al. Efficacy and patient-reported outcome measures from a two-part multicenter, placebo-controlled, randomized withdrawal trial of repository corticotropin injection for persistently active rheumatoid arthritis. European League Against Rheumatism. 2020:Poster FR10122.
   Google Scholar
• Ho-Mahler N, Turner B, Eaddy M, Hanke M, Nelson W. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/polymyositis. Open Access Rheumatol. 2020;12:21–28.
   PubMed Web of Science ®Google Scholar
• Hayes K, Panaccio MP, Houston P, et al. Real-world treatment patterns and outcomes from an electronic medical records database for patients with rheumatoid arthritis treated with repository corticotropin injection. Open Access Rheumatol. 2021;13:315–323.
   PubMed Web of Science ®Google Scholar
• Busch H, Wan GJ, Niewoehner J, et al. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis. Drugs Context. 2022;11:2021-10–4..
   Google Scholar
• Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. J Pharm Technol. 2017;33(4):151–155.
   PubMedGoogle Scholar
• Wu B, Deshpande G, Gu T, Popelar B, Philbin M, Wan GJ. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. J Med Econ. 2017;20(11):1170–1177.
   PubMed Web of Science ®Google Scholar
• Bindra J, Chopra I, Niewoehner J, Panaccio M, Wan GJ. Cost-effectiveness of repository corticotropin injection versus standard of care for the treatment of active rheumatoid arthritis. Clinicoecon Outcomes Res. 2021;13:349–358.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42(9):1785–1796.
   PubMedGoogle Scholar
• Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59(12):1788–1795.
   PubMedGoogle Scholar
• Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol Ther. 2020;7(4):893–908.
   PubMed Web of Science ®Google Scholar
• Askanase AD, Wan GJ, Panaccio MP, et al. Patient-reported outcomes from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial of repository corticotropin injection (Acthar®Gel) for persistently active systemic lupus erythematosus. Rheumatol Ther. 2021;8(1):573–584.
   PubMed Web of Science ®Google Scholar
• Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3(1):e000180.
   PubMed Web of Science ®Google Scholar
• Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23(9):905–912.
   PubMed Web of Science ®Google Scholar
• Becker P, Furie R, Mitrane M, Zhao E. THU0307 Repository corticotropin injection (RCI) attenuates disease activity in patients with persistently active systemic lupus erythematosus (SLE) requiring corticosteroids: results from a 44-week open-label extension study. Ann Rheum Dis. 2016;75(suppl 2):298–299.
   Google Scholar
• Bindra J, Chopra I, Hayes K, Niewoehner J, Panaccio M, Wan GJ. Cost-effectiveness of repository corticotropin injection versus standard of care for the treatment of exacerbations in moderate-to-severe systemic lupus erythematosus. Adv Ther. 2023;40(1):194–210.
   PubMed Web of Science ®Google Scholar
• Rice JB, White A, Galebach P, et al. The economic burden of dermatomyositis and polymyositis in the US [ACR abstract no. 1237]. Arthritis Rheumatol. 2016;68(suppl 10):1568–1569.
   PubMedGoogle Scholar
• Rice J, White A, Lopez A, et al. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. J Med Econ. 2016;19(7):649–654.
   PubMed Web of Science ®Google Scholar
• Levine T. Acthar in dermatomyositis and polymyositis treatment registry: an interim analysis. Neurology. 2015;84(suppl 14):7.065.
   Google Scholar
• Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77(5):720–727.
   PubMed Web of Science ®Google Scholar
• Knight T, Bond TC, Popelar B, et al. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobin, and/or rituximab. Clinicoecon Outcomes Res. 2017;9:271–279.
   PubMed Web of Science ®Google Scholar
• Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis—a rare disease often associated with systemic diseases and infections—a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7:57.
   PubMed Web of Science ®Google Scholar
• Yeung IY, Popp N, Chan CC. The role of sex in uveitis and ocular inflammation. Int Ophthalmol Clin. 2015;55(3):111–131.
   PubMedGoogle Scholar
• Albini T, Rice B, White A, et al. Clinical outcomes, healthcare resource use, and cost in patients with non-infectious inflammatory eye disease (NIIED) in a US population. Poster presented at: American Academy of Ophthalmology Annual Meeting (AAO 2017); November 11-14; 2017; New Orleans, LA.
   Google Scholar
• Albini TA, Rice JB, White AG, et al. Economic burden of non-infectious inflammatory eye disease (NIIED) in a commercially-insured population in the United States. Ocul Immunol Inflamm. 2020;28(1):164–174.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Anesi SD, Chexal S, et al. Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study. Acta Ophthalmol. 2021;99(6):669–678.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Skup M, Tundia N, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate posterior or panuveitis. Acta Ophthalmol. 2016;94(5):e331–339.
   PubMed Web of Science ®Google Scholar
• Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect. 2013;3(1):64.
   PubMedGoogle Scholar
• Nelson WW, Rice JB, White AG, et al. Predictors of high-cost patients with noninfectious inflammatory eye diseases. Clin Ther. 2019a;41(11):2331–2342.
   PubMed Web of Science ®Google Scholar
• Grieco G, McLaurin EB, Ousler GW, Liu J, Kacmaz O, Wirta D . Topline results from a multicenter, open-label, phase 4 study of RCI in patients with treatment-resistant severe non-infectious keratitis [ARVO abstract 3547077]. Invest Ophthalmol Vis Sci. 2021; 62 (8): 1275.
   Web of Science ®Google Scholar
• Wirta D, McLaurin E, Ousler G, Liu J, Kacmaz RO, Grieco J . Repository corticotropin injection (Acthar® Gel) for refractory severe noninfectious keratitis: efficacy and safety from a phase 4, multicenter, open-label study. Ophthalmol Ther. 2021;10(4):1077–1092.
   PubMed Web of Science ®Google Scholar
• Nelson WW, Lima AF, Kanya J, et al. Retrospective medical record review to describe use of repository corticotropin injection among patients with uveitis in the United States. J Ocul Pharmacol Ther. 2019b;35(3):182–188.
   PubMed Web of Science ®Google Scholar
• Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155–1167.
   PubMed Web of Science ®Google Scholar
• De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review. Semin Respir Crit Care Med. 2007;28(1):121–127.
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155):190146.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–322.
   PubMed Web of Science ®Google Scholar
• Chopra I, Qin Y, Kranyak J, et al. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records. Ther Adv Respir Dis. 2019;13:1753466619888127.
   Web of Science ®Google Scholar
• Baughman RP, Barney JB, O’Hare L, Lower EE. A retrospective pilot study examining the use of repository corticotropin injection in sarcoidosis patients. Respir Med. 2016;110:66–72.
   PubMed Web of Science ®Google Scholar
• Bindra J, Chopra I, Hayes K, Niewoehner J, Panaccio MP, Wan GJ. Understanding predictors of response to repository corticotropin injection treatment among patients with advanced symptomatic sarcoidosis. JHEOR. 2022;9(1):90–100.
   Google Scholar
• Wan G, Bindra J, Chopra I, Hayes K, Niewoehner J, Panaccio M. Repository corticotropin injection in African-Americans with advanced symptomatic sarcoidosis: a retrospective analysis of medical records. Poster presented at: American Thoracic Society (ATS). 2022; May 13-18, 2022; San Francisco, CA.
   Google Scholar
• Hogan J, Bomback AS, Mehta K, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2014;8(12):2072–2081.
   Web of Science ®Google Scholar
• Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58–67.
   PubMed Web of Science ®Google Scholar
• Alhamad T, Dieck JM, Younus U, et al. ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation. Transplantation. 2019;103(1):202–209.
   PubMed Web of Science ®Google Scholar
• Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AW, Khastgir A. Repository corticotropin injection in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016;17:37.
   PubMed Web of Science ®Google Scholar
• Tumlin J, Galphin C, Santos R, Rovin B. Safety and efficacy of combination ACTHar Gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Kidney Int Rep. 2017;2:924–932.
   PubMed Web of Science ®Google Scholar
• Zand L, Canetta P, Lafayette R, et al. An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression. Kidney Int Rep. 2020;5(1):58–65.
   PubMed Web of Science ®Google Scholar
• Nazareth T, Kariburyo F, Pirani A, et al. Patients with nephrotic syndrome (NS) receiving repository corticotropin injection (RCI) or rituximab (RTX): real-world evidence from a US claims analysis. Poster presented at: Annual Spring Clinical Meetings of the National Kidney Foundation. April 18-22, 2017b; Buena Vista, FL.
   Google Scholar